Diagnostic value of ANXA2 in serum and pleural effusion in patients with lung cancer

Gao-wa JIN,Ying-chun QIN,Yong-li GE,Wei LUAN,Gao-wa WUYUN

DOI: https://doi.org/10.3969/j.issn.1009-6663.2017.05.014

2017-01-01

Abstract:Objective To estimate the diagnosis value of ANXA2 in serum and pleural effusion in patients with lung cancer. Methods 60 lung cancer patients and 40 pneumonia benign disease patients were enroll in this study. The levels of ANXA2 in serum and pleural effusion were measured and recorded. Correlation analysis was used to evaluate the association between ANXA2 and tumor stage, lymphatic metastasis and distant metastasis. Results The levels of ANXA2 in serum and pleural effusion in the lung cancer group were significantly higher than those in the control group ( serum:32. 3 ± 14. 0 ng/mL vs. 16. 8 ± 6. 5 ng/mL, P<0. 05; pleural effusion:66. 8 ± 14. 7 ng/mL vs. 25. 2 ± 12. 6 ng/mL, P<0. 05). The contents of serum ANXA2 were higher than those of pleural effusion in lung cancer patients (32. 3 ± 14. 0 ng/mL vs. 76. 8 ± 14. 7 ng/mL, P<0. 05). In comparison with stageⅢ-Ⅳpatients, the ANXA2 levels of both serum and pleural effusion in Ⅰ-Ⅱ patients were increased( serum:29. 1 ± 12. 1 ng/mL vs. 34. 7 ± 16. 2 ng/mL,P<0. 05;pleural effusion: 61. 6 ± 18. 8 ng/mL vs. 78. 5 ± 11. 7 ng/mL,P<0. 05). The lung cancer patients with lymphatic metastasis had a higher levels of ANXA2 in serum and pleural effusion compared with those without lymphatic metastasis (serum:35. 2 ± 16. 1ng/mL vs. 30. 5 ± 11. 3 ng/mL, P<0. 05; pleural ef-fusion:88. 6 ± 20. 7 ng/mL vs. 59. 3 ± 11. 5 ng/mL, P<0. 05). ROC analysis showed that the AUC for lung cancer diagnosis of serum and pleural effusion of ANXA2 were 0. 712 and 0. 822 respectively, which cut-off value were 40. 2 ng/mL and 78. 2 ng/mL, respectively. Correlation analysis showed that both serum and pleural effusion of ANXA2 were positively related with lung cancer (serum:0. 706, P<0. 05; pleural effusion: r=0. 812, P<0. 05). Con-clusion The levels of serum and pleural effusion ANXA2 are elevated in lung cancer patients, which may be used for early detection and stage prognosis.